Summary
The adoptive immunotherapy of human cancer using lymphokine-activated killer (LAK) cells in combination with high-dose systemic recombinant interleukin-2 (rIL-2) has been associated with global changes in several hematological and immunological parameters while imposing profound toxicity on patients. We have evaluated an alternative LAK cell therapy utilizing low-dose systemic rIL-2 in 27 consecutive patients with metastatic cancer. We report that the administration of systemic low-dose rIL-2 is also characterized by significant changes in immunological and hematological parameters, which are qualitatively similar to those induced by high-dose rIL-2. Low-dose systemic rIL-2, given by i.v. bolus, is cleared to baseline levels within 240 min of administration. The induction of lymphocytosis and eosinophilia, which has characterized other protocols, is also a feature of this protocol. In addition, low-dose systemic rIL-2/LAK cell immunotherapy results in increased peripheral blood mononuclear cell (PBMC) expression of T-cell activation markers such as OKIa, OKT10 and IL-2 receptor. PBMC sampled approximately 100 h after the final infusion of LAK cells demonstrated a statistically significant increase in their ability to kill natural killer (NK)-sensitive and NK-resistent cell lines such as K562 and Daudi compared to baseline values (P <.05). These data suggest that rIL-2-based immunotherapy using low-dose rIL-2 is capable of inducing quantitative hematological and immunological changes while (in combination with LAK cells) retaining the ability to mediate tumor regressionin vivo.
Similar content being viewed by others
References
Atkins MB, Gould JA, Allegretta M, Li JJ, Dempsey RA, Rudders RA, Parkinson DR, Reichlin S, Mier JW (1986) Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 4: 1380
Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, Hawkins MJ, Atkins MB, Ciobanu N, Ellis TM (1987) Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res 48: 4409
Cheever MA, Greenberg PD, Fefer A (1980) Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 125: 711
Domzig W, Stadler BM, Herberman RB (1983) Interleukin-2 dependence of human natural (NK) killer cell activity. J Immunol 130: 1970
Eberlein TJ, Rosenstein M, Rosenberg SA (1982) Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin-2. J Exp Med 156: 385
Eberlein TJ, Schoof DD, Jung S-E, Davidson DL, Gramolini B, McGrath K, Massaro AF, Wilson RE (1988) A new regimen of interleukin-2 and lymphokine-activated killer cells: efficacy without significant toxicity. Arch Intern Med 148: 2571
Eberlein TJ, Schoof DD, Michie HR, Massaro AF, Burger U, Wilmore DW, Wilson RE (1988) Ibuprofen causes reduced toxicity of IL-2 administration in patients with metastatic cancer. Arch Surg 124: 542
Emmrich F, Moll H, Simon MM (1985) Recombinant human interleukin-2 acts as a B-cell growth and differentiation promoting factor. Immunobiology 169: 97
Fernandez-Cruz E, Halliburton B, Feldman JD (1979) In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J Immunol 123: 1772
Gillis S, Smith KA (1977) Long-term culture of tumor-specific cytotoxic T-cells. Nature 268: 154
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) The lymphokine-activated killer cell phenomenon: lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 55: 1823
Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL (1988) A phase I study of recombinant interleukin 2 plus recombinant beta-interferon. Cancer Res 48: 3875
Lotze MT, Custer MC, Rosenberg SA (1986) Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 121: 1373
Morgan DA, Ruscetti FW, Gallo RC (1976) Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 193: 1007
Rosenberg SA (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485
Rosenberg SA (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889
Rosenberg SA, Grimm E, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF (1984) Biological activity of recombinant human interleukin-2 produced inEscherichia coli. Science 223: 1412
Schoof DD, Gramolini B, Davidson D, Massaro A, Wilson RE, Eberlein TJ (1988) Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48: 5007
Silberstein DS, Schoof DD, Rodrick ML, Gramolini BA, Tai P, Spry CJ, David JR, Eberlein TJ (1989) Characteristics of eosinophils in cancer patients treated with interleukin-2 generated LAK cells. J Immunol (in press)
Taniguchi R, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuor J (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302: 305
Watson J (1979) Continuous proliferation of murine antigenspecific helper T-lymphocytes in culture. J Exp Med 150: 1510
West WH (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898
Author information
Authors and Affiliations
Additional information
Dr. Eberlein was a recipient of an American Cancer Society Career Development Award. This work is supported in part by NIH Grant CA-40555 and the Clinical Research Center Grant 20-9299
Rights and permissions
About this article
Cite this article
Eberlein, T.J., Rodrick, M.L., Massaro, A.F. et al. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Immunol Immunother 30, 145–150 (1989). https://doi.org/10.1007/BF01669422
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01669422